Zofran Birth Defect Lawsuit Alleges Drug Caused Multiple Congenital Defects

December 10, 2015 – – ZofranLegal.com reports on the details of another lawsuit filed against anti-nausea drug manufacturer GlaxoSmithKline and Zofran. Similarly to over 160 other lawsuits filed against Zofran, this complaint alleges that a fetus’s’ exposure to the drug while growing in utero caused them to develop “numerous congenital defects.” The claim was filed by the infant’s mother in the U.S. District Court for the Eastern District of Louisiana under number 2:15-cv-04399-SM-DEK on September 14th, 2015.

Details of the complaint note that the mother seeks damages from pharmaceutical giant GlaxoSmithKline, who manufactures and markets Zofran. Her claim states, as multiple others do, that GSK purposefully hid mounting evidence linking anti-nausea medicine Zofran to the development of birth defects in babies in the womb. The details of her story are tragic ones, which other plaintiffs in the mounting lawsuits appear to be far too familiar with.

In her complaint, the mother explains that she was prescribed Zofran in order to treat severe nausea during the first trimester of her pregnancy. Coincidentally, the first trimester is also a time when the fetus does much of its limb, heart, and mouth development. After using Zofran during this time period, the mother later gave birth to a son who was diagnosed with severe birth defects, including bilateral clubfeet, respiratory distress syndrome, apnea, and cleft palate.

In other lawsuits against GSK and Zofran, birth defects in babies most commonly linked to exposure to the drug include cleft lip and palate, atrial septal defect and ventricular septal defect, transposition of the greater vessels, tetralogy of fallot, clubfoot, kidney defects, and respiratory distress. Some mothers allege that their babies defects were fatal, while others indicate that they required multiple corrective surgeries. In the case of this plaintiff, her son required two surgeries to address his defects.

Lawsuits continue to grow concerning Zofran and birth defects. They have been consolidated at this time by the JPML to form multidistrict litigation number 2657 in Boston, Massachusetts. They will be overseen by Judge F. Dennis Saylor IV, and are expected to continue to grow in number.

At this time, the attorneys at Monheit Law are working to assist anyone who may have used zofran while pregnant and who later gave birth to a child with defects. The drug was never FDA-approved to treat expectant mothers, or tested for safety on this consumer group, and so these mothers and their children may be entitled to significant compensation. At this time, the attorneys at Monheit Law are offering complimentary consultations to those involved.

To obtain more information on zofran birth defects, get updates on the litigation, or to ask questions, please call Michael Monheit, Esq. at 877-620-8411.

###

Contact ZofranLegal.com:

Michael Monheit
1-877-620-8411
michael@monheit.com
1368 Barrowdale Road, Rydal, PA 19046

ReleaseID: 60006204